AptarGroup, Inc.

NYSE:ATR Rapport sur les actions

Capitalisation boursière : US$7.9b

AptarGroup Croissance future

Future contrôle des critères 1/6

AptarGroup devrait augmenter ses bénéfices et son chiffre d'affaires de 10.2% et de 5.7% par an respectivement. Le BPA devrait croître de de 9.6% par an. Le rendement des capitaux propres devrait être 12.8% dans 3 ans.

Informations clés

10.2%

Taux de croissance des bénéfices

9.59%

Taux de croissance du BPA

Packaging croissance des bénéfices23.9%
Taux de croissance des recettes5.7%
Rendement futur des capitaux propres12.80%
Couverture par les analystes

Good

Dernière mise à jour03 Aug 2026

Mises à jour récentes de la croissance future

Article d’analyse • May 03

Analyst Estimates: Here's What Brokers Think Of AptarGroup, Inc. (NYSE:ATR) After Its First-Quarter Report

Shareholders might have noticed that AptarGroup, Inc. ( NYSE:ATR ) filed its first-quarter result this time last week...

Recent updates

Mise à jour du récit • Aug 16

ATR: Recent Buybacks Will Support Future Upside Over The Coming Years

Analysts have lifted their price target on AptarGroup from $144 to $155, reflecting updated assumptions for slightly higher revenue growth, a modestly adjusted discount rate, and a broadly similar future P/E and profit margin profile. What’s in the News for AptarGroup AptarGroup reported that from April 1, 2026 to June 30, 2026, it repurchased 403,344 shares for US$50 million, representing 0.63% of its shares under the current buyback program.
Mise à jour du récit • Aug 02

ATR: Share Repurchases And Refillable Packaging Will Support Attractive Future Returns

The analyst price target for AptarGroup has been adjusted from about $161.43 to about $165.29. Analysts point to updated assumptions around revenue growth, profit margins, and a slightly different forward P/E multiple as the key drivers of this change.
Seeking Alpha • Jun 29

AptarGroup Has Fallen Enough (Rating Upgrade)

Summary AptarGroup is upgraded from 'sell' to 'hold' as valuation improves after a significant share price decline. ATR's Q1 revenue rose 10.8% to $982.9M, but most growth was driven by FX and acquisitions, not organic expansion. Cash flows and EBITDA improved despite margin compression and net profit declines, particularly due to Beauty segment strength. ATR trades at a premium to peers, justified by its niche positioning, but not enough for a 'buy' rating. Read the full article on Seeking Alpha
Article d’analyse • Jun 18

AptarGroup (ATR) Stock Could Be 25.5% Undervalued on Its Drug Delivery Growth Narrative

Why AptarGroup Stock Is Back On Investor Radars AptarGroup (ATR) has drawn interest after recent share price moves, with the stock gaining about 6% over the past month while still showing a decline over the past year. For investors tracking AptarGroup as a packaging and drug delivery supplier, those mixed return figures may prompt a closer look at how its current valuation lines up with recent business performance and market expectations. See our latest analysis for AptarGroup. With the share...
Mise à jour du récit • Jun 17

ATR: Healthcare Packaging And Refillable Beauty Will Drive Future Upside Potential

The analyst price target for AptarGroup has been adjusted slightly to $211.14 from $211.25. Analysts cite updated assumptions for revenue growth, profit margins and the future P/E multiple as the main drivers of the change.
Mise à jour du récit • Jun 03

ATR: Healthcare Packaging And Refillable Beauty Will Support Future Upside Potential

Analysts have nudged their price target for AptarGroup higher by refining assumptions on revenue growth to 6.11%, profit margin to 9.78%, and a future P/E of 33.28x. This lifts their valuation outlook without changing the underlying fair value estimate of $211.25 per share.
Mise à jour du récit • May 12

ATR: Refillable Beauty And Nasal Drug Delivery Will Support Upside Potential

AptarGroup's updated analyst price target has edged down by about $1.54 to reflect slightly higher discount rate assumptions, along with modest adjustments to projected revenue growth, profit margins, and future P/E expectations, according to analysts. What's in the News AptarGroup and Clarins rolled out a custom reloadable airless packaging solution for Clarins Total Eye Lift Eye Cream, using Aptar Beauty’s patented Gaïa technology to support lower material usage while maintaining formula protection and a premium look.
Article d’analyse • May 03

Analyst Estimates: Here's What Brokers Think Of AptarGroup, Inc. (NYSE:ATR) After Its First-Quarter Report

Shareholders might have noticed that AptarGroup, Inc. ( NYSE:ATR ) filed its first-quarter result this time last week...
Mise à jour du récit • Apr 28

ATR: Nasal Therapies And Share Buybacks Will Support Future Upside

Analysts have kept their $144.00 price target on AptarGroup unchanged, citing relatively steady assumptions around discount rate, revenue growth, profit margin, and future P/E. These factors support the view that the stock’s current valuation framework still holds.
Mise à jour du récit • Apr 14

ATR: Nasal Drug Delivery Pipeline And Leadership Transition Will Shape Future Upside

Analysts have reaffirmed AptarGroup's price target at $144.00, citing updated assumptions for discount rates, revenue growth, profit margins and future P/E that together suggest a steady view of the company’s valuation. What's in the News AptarGroup’s Unidose Powder Nasal Spray System is being used in ENA Respiratory’s Phase II study of INNA-051, an investigational once-weekly nasal spray aimed at helping protect adults at higher risk from symptomatic viral respiratory infections (Key Developments).
Mise à jour du récit • Mar 30

ATR: Nasal And Eye Care Drug Delivery Will Drive Future Upside

Analysts have raised their price target on AptarGroup from $133 to $144. This reflects updated views on its fair value based on revised assumptions for discount rate, revenue growth, profit margin, and future P/E.
Mise à jour du récit • Mar 16

ATR: Share Repurchases Will Support Upside Potential In Drug Delivery Portfolio

Analysts have modestly revised their price target on AptarGroup, keeping fair value steady at about $212.79 while fine tuning assumptions on discount rate, revenue growth, profit margin and future P/E. This reflects updated views on the company’s risk profile and earnings potential.
Mise à jour du récit • Mar 02

ATR: Share Repurchases And Nasal Drug Delivery Portfolio Will Support Upside Potential

Analysts have trimmed their price target on AptarGroup slightly to about $213, reflecting updated assumptions around a modestly higher discount rate, a small change in estimated fair value and adjusted expectations for revenue growth, profit margins and future P/E levels. What's in the News AptarGroup issued earnings guidance for the first quarter of 2026, with earnings per share framed using a 1.18 EUR to US$ exchange rate assumption.
Mise à jour du récit • Feb 16

ATR: Drug Delivery Platforms And Buybacks Will Support Attractive Future Returns

Analysts have raised their price target for AptarGroup to $161.43 from $159.14, reflecting updated views on the company’s discount rate, revenue growth assumptions, profit margin outlook, and future P/E expectations. What's in the News AptarGroup issued earnings guidance for the first quarter of 2026, with earnings per share framed using a 1.18 EUR to US$ exchange rate assumption.
Mise à jour du récit • Feb 02

ATR: Nasal And Eye Care Drug Delivery Platforms Will Support Balanced Outlook

AptarGroup's analyst price target has changed from US$153 to US$133 as analysts incorporate updated assumptions for the discount rate, revenue growth, profit margin, and future P/E. What's in the News AptarGroup's LuerVax and Spray Divider nasal delivery systems are being used in CastleVax's Phase II clinical trial of CVAX-01, an intranasal COVID-19 vaccine candidate that is being assessed against an FDA approved injectable mRNA vaccine in around 200 U.S. adults, including higher risk and older participants (Key Developments).
Mise à jour du récit • Jan 19

ATR: Nasal And Eye Drug Delivery Platforms Will Support Attractive Future Returns

Analysts have trimmed their price target on AptarGroup to about $159 from roughly $161, reflecting slightly adjusted assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E that remain broadly consistent with prior views. What's in the News AptarGroup’s nasal vaccine delivery systems, LuerVax and Spray Divider, are being used in CastleVax’s Phase II clinical trial of CVAX-01, an intranasal COVID-19 vaccine candidate assessing safety, tolerability and immune response versus an FDA approved injectable mRNA vaccine in about 200 U.S. adults, including higher risk and older participants (Key Developments).
Mise à jour du récit • Jan 05

ATR: Pharma Nasal Delivery Momentum Will Drive Attractive Long Term Returns

Narrative Update on AptarGroup Analyst Price Target Analysts have modestly raised their price target for AptarGroup to approximately 161.43 dollars, reflecting slightly higher long term return expectations and a marginally richer future earnings multiple. What's in the News Aptar's Bidose liquid nasal spray system has been selected to deliver the newly FDA approved CARDAMYST nasal spray for acute PSVT episodes in adults, which underscores Aptar's role in emergency cardiovascular therapies (FDA announcement) The company completed a 1.50 million share repurchase, about 2.27 percent of shares outstanding, for approximately 227.34 million dollars under its October 2024 buyback program, which signals continued capital return to shareholders (company disclosure) Nasus Pharma extended and updated its long running collaboration with Aptar through a new master services agreement that covers development, analytical, regulatory, and consulting support for its intranasal epinephrine program using Aptar's unit dose powder nasal delivery system (Nasus Pharma announcement) A new supply agreement makes Aptar France the exclusive provider of UDSp devices to Nasus Pharma for its intranasal epinephrine products, with milestone payments and royalties tied to NDA submission, approval, and commercial sales (Nasus Pharma announcement) Valuation Changes Fair value estimate: unchanged at approximately 161.43 dollars per share, indicating no revision to the intrinsic value assessment.
Article d’analyse • Jan 02

We Like These Underlying Return On Capital Trends At AptarGroup (NYSE:ATR)

To find a multi-bagger stock, what are the underlying trends we should look for in a business? In a perfect world, we'd...
Mise à jour du récit • Dec 15

ATR: Share Repurchases And Nasal Drug Delivery Partnership Will Support Upside Potential

Narrative Update Analysts have modestly reduced their price target on AptarGroup, trimming fair value expectations from approximately $220.00 to about $213.03. They cite updated assumptions for slower revenue growth, slightly lower profit margins, and a higher future price to earnings multiple within their discounted cash flow framework.
Mise à jour du récit • Nov 30

ATR: Share Buyback and Expanded Pharma Partnerships Will Drive Future Upside

Analysts have slightly raised their price target for AptarGroup to $161.43, citing a modest increase in expected profit margins as well as an updated outlook on revenue growth and future price-to-earnings ratios. What's in the News Between July and September 2025, AptarGroup completed the repurchase of over 1.5 million shares for approximately $227.34 million as part of its ongoing buyback program (Company Filing).
Mise à jour du récit • Nov 16

ATR: Share Buyback and Pharma Supply Moves Will Unlock Upside

Narrative Update on AptarGroup Price Target Analysts have revised AptarGroup’s fair value estimate downward by approximately $9 to $161.43 per share, citing tempered growth projections and a modest increase in the discount rate as key factors behind the adjustment. What's in the News Completed share repurchases totaling 1,504,552 shares for $227.34 million under the buyback announced on October 10, 2024 (Buyback Tranche Update).
Mise à jour du récit • Nov 01

ATR: Expanded Partnership Agreements Will Drive Long-Term Healthcare Solutions

Analysts have revised their price target for AptarGroup downward from $177 to $170.71. They cited modest changes in discount rate expectations, a slight increase in projected revenue growth, and softer projected profit margins and future valuation multiples.
Article d’analyse • Oct 18

AptarGroup (NYSE:ATR) Is Increasing Its Dividend To $0.48

The board of AptarGroup, Inc. ( NYSE:ATR ) has announced that it will be increasing its dividend by 6.7% on the 13th of...
Mise à jour du récit • Sep 05

Advanced Drug Delivery And Sustainable Packaging Will Transform Global Healthcare

The uptick in AptarGroup’s consensus price target to $178.43 is primarily driven by a modest increase in its forward P/E multiple, while revenue growth expectations remain stable. What's in the News Held Analyst/Investor Day.

Prévisions de croissance des bénéfices et des revenus

NYSE:ATR - Estimations futures des analystes et données financières antérieures (USD Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
12/31/20284,4714394548293
12/31/20274,1434014447177
12/31/20263,9823423495078
6/30/20263,933363308583N/A
3/31/20263,873387324606N/A
12/31/20253,777393295570N/A
9/30/20253,663419306565N/A
6/30/20253,611392342616N/A
3/31/20253,555370356634N/A
12/31/20243,583375349643N/A
9/30/20243,573336378685N/A
6/30/20243,557320323629N/A
3/31/20243,543313254569N/A
12/31/20233,487284257575N/A
9/30/20233,445281209528N/A
6/30/20233,389251159484N/A
3/31/20233,337232164485N/A
12/31/20223,322239163479N/A
9/30/20223,34023888410N/A
6/30/20223,32923146365N/A
3/31/20223,29522366383N/A
12/31/20213,22724456363N/A
9/30/20213,163240156448N/A
6/30/20213,096256256518N/A
3/31/20212,985243307557N/A
12/31/20202,929214318570N/A
9/30/20202,851209283516N/A
6/30/20202,793202273521N/A
3/31/20202,837234N/A522N/A
12/31/20192,860242N/A514N/A
9/30/20192,873234N/A484N/A
6/30/20192,838217N/A380N/A
3/31/20192,806198N/A340N/A
12/31/20182,765195N/A314N/A
9/30/20182,706204N/A269N/A
6/30/20182,664218N/A330N/A
3/31/20182,571228N/A338N/A
12/31/20172,469220N/A325N/A
9/30/20172,382220N/A388N/A
6/30/20172,348220N/A390N/A
3/31/20172,350214N/A352N/A
12/31/20162,331206N/A325N/A
9/30/20162,339199N/A296N/A
6/30/20162,335200N/A269N/A
3/31/20162,310198N/A297N/A
12/31/20152,317199N/A324N/A
9/30/20152,370198N/A346N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de ATR ( 10.2% par an) est supérieure au taux d'épargne ( 3.7% ).

Bénéfices vs marché: Les bénéfices de ATR ( 10.2% par an) devraient croître plus lentement que le marché US ( 17.4% par an).

Croissance élevée des bénéfices: Les bénéfices de ATR devraient augmenter, mais pas de manière significative.

Chiffre d'affaires vs marché: Le chiffre d'affaires de ATR ( 5.7% par an) devrait croître plus lentement que le marché de US ( 13.6% par an).

Croissance élevée des revenus: Le chiffre d'affaires de ATR ( 5.7% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de ATR devrait être faible dans 3 ans ( 12.8 %).

Découvrir les entreprises en croissance

7D

1Y

7D

1Y

7D

1Y

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2026/09/21 06:41
Cours de l'action en fin de journée2026/09/18 00:00
Les revenus2026/06/30
Revenus annuels2025/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.

Découvrez l' qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

AptarGroup, Inc. est couverte par 16 analystes. 8 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Ghansham PanjabiBaird
Mark WildeBMO Capital Markets Equity Research
George StaphosBofA Global Research